FULC
Fulcrum Therapeutics, Inc.
Key Financials
Revenue
$7.8M
N/A
Operating Income
$-84769000
↓ 287.1%
Net Income
$-74880000
↓ 670.0%
EPS (Diluted)
$-1.18
↓ 637.5%
Total Liabilities
$17.3M
↓ 2.3%
Total Assets
$366.3M
↑ 40.5%
Cash & Equivalents
$197.5M
↑ 239.3%
Shareholders' Equity
$349.0M
↑ 43.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| SCHEDULE 13G | 8/3/2026 | View on SEC |
| 10-Q | 7/30/2026 | View on SEC |
| SCHEDULE 13G/A | 7/28/2026 | View on SEC |
| 4 | 7/20/2026 | View on SEC |
| SCHEDULE 13G | 7/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FULC |
| Company Name | Fulcrum Therapeutics, Inc. |
| CIK | 1680581 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-651-8851 |